Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Bispecific antibodies were associated with improved clinical benefit (odds ratio, 1.95; 95% CI, 1.23-4.15), whereas PIK3CA alterations were associated with reduced benefit (odds ratio, 0.03; 95% CI, 0.00-0.51).
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability